DD295363A5 - Verfahren zur herstellung von 1-benzyl-indazol-3-yl-zwischenprodukten - Google Patents

Verfahren zur herstellung von 1-benzyl-indazol-3-yl-zwischenprodukten Download PDF

Info

Publication number: DD295363A5
Authority: DD; German Democratic Republic
Prior art keywords: benzyl; general formula; indazole; acid; hydroxymethyl
Prior art date: 1989-02-07

Application number

DD90342349A

Other languages

German (de)

English (en)

Inventor

Bruno Silvestrini

Leandro Baiocchi

Original Assignee

��@��@��@��@��@�K@�K@�K@�K@�K@�K@�K@�Kk��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-07

Filing date

1990-02-07

Publication date

1991-10-31

1990-02-07 Application filed by ��@��@��@��@��@�K@�K@�K@�K@�K@�K@�K@�Kk�� filed Critical ��@��@��@��@��@�K@�K@�K@�K@�K@�K@�K@�Kk��

1991-10-31 Publication of DD295363A5 publication Critical patent/DD295363A5/de

Links

238000000034 method Methods 0.000 title claims abstract description 19
-1 1-BENZYL-INDAZOL-3-YL Chemical class 0.000 title abstract description 14
239000013067 intermediate product Substances 0.000 title 1
230000008569 process Effects 0.000 claims abstract description 8
238000002360 preparation method Methods 0.000 claims abstract description 5
150000001875 compounds Chemical class 0.000 claims description 26
239000002253 acid Substances 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 4
125000003118 aryl group Chemical group 0.000 claims description 4
239000003513 alkali Substances 0.000 claims description 3
125000004429 atom Chemical group 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims 1
239000000543 intermediate Substances 0.000 abstract description 8
230000000202 analgesic effect Effects 0.000 abstract description 5
238000004519 manufacturing process Methods 0.000 abstract description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
239000000203 mixture Substances 0.000 description 15
241001465754 Metazoa Species 0.000 description 14
239000011541 reaction mixture Substances 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
239000002904 solvent Substances 0.000 description 12
150000003839 salts Chemical class 0.000 description 10
AKQDXNFPEFHRLS-UHFFFAOYSA-N (1-benzylindazol-3-yl)methanol Chemical compound C12=CC=CC=C2C(CO)=NN1CC1=CC=CC=C1 AKQDXNFPEFHRLS-UHFFFAOYSA-N 0.000 description 9
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
238000012360 testing method Methods 0.000 description 9
239000000243 solution Substances 0.000 description 8
238000009835 boiling Methods 0.000 description 7
230000035484 reaction time Effects 0.000 description 7
238000011282 treatment Methods 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
239000000047 product Substances 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
239000008177 pharmaceutical agent Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
150000001340 alkali metals Chemical class 0.000 description 4
BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 4
229960005149 bendazac Drugs 0.000 description 4
239000000460 chlorine Substances 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
239000002243 precursor Substances 0.000 description 4
150000003254 radicals Chemical class 0.000 description 4
238000010992 reflux Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000011734 sodium Substances 0.000 description 4
229910000104 sodium hydride Inorganic materials 0.000 description 4
239000007787 solid Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
229910052783 alkali metal Inorganic materials 0.000 description 3
150000004703 alkoxides Chemical class 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000002585 base Substances 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
239000012280 lithium aluminium hydride Substances 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
235000011121 sodium hydroxide Nutrition 0.000 description 3
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical class C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
MBIQENSCDNJOIY-UHFFFAOYSA-N 2-hydroxy-2-methylbutyric acid Chemical compound CCC(C)(O)C(O)=O MBIQENSCDNJOIY-UHFFFAOYSA-N 0.000 description 2
RHLVCLIPMVJYKS-UHFFFAOYSA-N 3-octanone Chemical compound CCCCCC(=O)CC RHLVCLIPMVJYKS-UHFFFAOYSA-N 0.000 description 2
HCFAJYNVAYBARA-UHFFFAOYSA-N 4-heptanone Chemical compound CCCC(=O)CCC HCFAJYNVAYBARA-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
240000002989 Euphorbia neriifolia Species 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
CATSNJVOTSVZJV-UHFFFAOYSA-N Heptan-2-one Natural products CCCCCC(C)=O CATSNJVOTSVZJV-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
241001178520 Stomatepia mongo Species 0.000 description 2
230000003187 abdominal effect Effects 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000008602 contraction Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
125000004494 ethyl ester group Chemical group 0.000 description 2
NGAZZOYFWWSOGK-UHFFFAOYSA-N ethyl-n-butyl-ketone Natural products CCCCC(=O)CC NGAZZOYFWWSOGK-UHFFFAOYSA-N 0.000 description 2
210000002683 foot Anatomy 0.000 description 2
235000019256 formaldehyde Nutrition 0.000 description 2
229960004279 formaldehyde Drugs 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
239000007788 liquid Substances 0.000 description 2
XNLICIUVMPYHGG-UHFFFAOYSA-N methyl n-propyl ketone Natural products CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
239000011591 potassium Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
238000005303 weighing Methods 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
KGKSTPKEAQNJJD-UHFFFAOYSA-N 1-bromo-3-methylpent-1-yn-3-ol Chemical compound CCC(C)(O)C#CBr KGKSTPKEAQNJJD-UHFFFAOYSA-N 0.000 description 1
BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
NFAIOOKNXAXEBY-UHFFFAOYSA-N 2h-indazol-3-ylmethanol Chemical compound C1=CC=CC2=C(CO)NN=C21 NFAIOOKNXAXEBY-UHFFFAOYSA-N 0.000 description 1
ZPQAKYPOZRXKFA-UHFFFAOYSA-N 6-Undecanone Chemical compound CCCCCC(=O)CCCCC ZPQAKYPOZRXKFA-UHFFFAOYSA-N 0.000 description 1
241000272814 Anser sp. Species 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229920005439 Perspex® Polymers 0.000 description 1
235000017276 Salvia Nutrition 0.000 description 1
240000007164 Salvia officinalis Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
208000033809 Suppuration Diseases 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229960003767 alanine Drugs 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
229910000272 alkali metal oxide Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
229960003121 arginine Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960005261 aspartic acid Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000010009 beating Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical class [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
235000011116 calcium hydroxide Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
229960002433 cysteine Drugs 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229940116333 ethyl lactate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
229960002885 histidine Drugs 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
238000011905 homologation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
229960003136 leucine Drugs 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
239000000155 melt Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
WSGCRAOTEDLMFQ-UHFFFAOYSA-N nonan-5-one Chemical compound CCCCC(=O)CCCC WSGCRAOTEDLMFQ-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
238000013021 overheating Methods 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960005190 phenylalanine Drugs 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229910000105 potassium hydride Inorganic materials 0.000 description 1
235000011118 potassium hydroxide Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
229960001153 serine Drugs 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
229960002898 threonine Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
229960004441 tyrosine Drugs 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
229960004295 valine Drugs 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000007279 water homeostasis Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Thiazole And Isothizaole Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

DD90342349A 1989-02-07 1990-02-07 Verfahren zur herstellung von 1-benzyl-indazol-3-yl-zwischenprodukten DD295363A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT8947620A IT1230441B (it)	1989-02-07	1989-02-07	Eteri della serie dell'indazolo

Publications (1)

Publication Number	Publication Date
DD295363A5 true DD295363A5 (de)	1991-10-31

Family

ID=11261479

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DD90342349A DD295363A5 (de)	1989-02-07	1990-02-07	Verfahren zur herstellung von 1-benzyl-indazol-3-yl-zwischenprodukten
DD90337657A DD291995A5 (de)	1989-02-07	1990-02-07	Verfahren zur herstellung von aethern der verbindung 1-benzyl-3-hydroxy-methyl-indazol mit aliphatischen 2-hydroxysaeuren

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DD90337657A DD291995A5 (de)	1989-02-07	1990-02-07	Verfahren zur herstellung von aethern der verbindung 1-benzyl-3-hydroxy-methyl-indazol mit aliphatischen 2-hydroxysaeuren

Country Status (36)

Country	Link
US (2)	US4999367A (fr)
EP (1)	EP0382276B1 (fr)
JP (1)	JP2870925B2 (fr)
KR (1)	KR0145525B1 (fr)
CN (2)	CN1046505C (fr)
AR (1)	AR247386A1 (fr)
AT (1)	ATE127115T1 (fr)
AU (1)	AU624895B2 (fr)
BG (1)	BG50273A3 (fr)
CA (1)	CA2009503C (fr)
CZ (1)	CZ280121B6 (fr)
DD (2)	DD295363A5 (fr)
DE (2)	DE69021902T2 (fr)
DK (1)	DK0382276T3 (fr)
EG (1)	EG19170A (fr)
ES (1)	ES2020171T3 (fr)
FI (1)	FI102678B (fr)
GE (1)	GEP19971030B (fr)
GR (2)	GR910300073T1 (fr)
HU (1)	HU204793B (fr)
IL (1)	IL93132A (fr)
IN (1)	IN170957B (fr)
IT (1)	IT1230441B (fr)
LT (1)	LT3604B (fr)
LV (1)	LV10612B (fr)
NZ (1)	NZ232258A (fr)
PE (1)	PE25091A1 (fr)
PH (1)	PH26552A (fr)
PL (2)	PL163730B1 (fr)
PT (1)	PT93067B (fr)
RO (1)	RO106252B1 (fr)
RU (3)	RU2066318C1 (fr)
SK (1)	SK56390A3 (fr)
UA (1)	UA26852C2 (fr)
YU (1)	YU47943B (fr)
ZA (1)	ZA90644B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1253703B (it) *	1991-04-22	1995-08-23	Angelini Francesco Ist Ricerca	Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1293795B1 (it) *	1997-07-28	1999-03-10	Angelini Ricerche Spa	Farmaco attivo nel ridurre la produzione di proteina mcp-1
US5943270A (en) *	1997-11-26	1999-08-24	Intel Corporation	Two-transistor DRAM cell for logic process technology
US7514463B2 (en) *	2004-08-20	2009-04-07	University Of Kansas	Lonidamine analogues and their use in male contraception and cancer treatment
ITMI20062254A1 (it)	2006-11-24	2008-05-25	Acraf	Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
EP2262778B8 (fr)	2008-03-07	2020-01-01	Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.	Dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement de maladies basées sur l'expression de mcp-1, cx3cr1 et p40
US8314099B2 (en)	2008-03-07	2012-11-20	Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.	1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1 and CX3CR1
PL2254870T3 (pl) *	2008-03-07	2016-07-29	Acraf	Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1
PL2462119T3 (pl) *	2009-08-03	2014-10-31	Acraf	Sposób wytwarzania 1-benzylo-3-hydroksymetylo-1H-indazolu i jego pochodnych oraz potrzebnych magnezowych związków pośrednich
UA108742C2 (uk) *	2009-09-23	2015-06-10		Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
EP2844250B1 (fr)	2012-05-01	2017-11-08	Translatum Medicus Inc.	Procédé de traitement et de diagnostic de maladies menant à la cécité
US8999292B2 (en)	2012-05-01	2015-04-07	Translatum Medicus Inc.	Methods for treating and diagnosing blinding eye diseases
JP2015521183A (ja)	2012-05-18	2015-07-27	サノフイ	ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用
EP2882715B1 (fr)	2012-05-18	2016-11-09	Sanofi	Dérivés de pyrazole et leur utilisation en tant qu'antagonistes lpar5
CN108047136B (zh) *	2017-12-20	2021-07-09	长春普华制药股份有限公司	一种苄达酸的精制方法
EP3990433A4 (fr)	2019-06-25	2023-07-26	Translatum Medicus Inc.	Procédés de fabrication d'acide 2-((1-benzyl-1h-indazol-3-yl)méthoxy)-2-méthylpropanoïque et de ses dérivés
CN113929627A (zh) *	2021-10-19	2022-01-14	吕梁学院	一种宾达利的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL28032A (en) *	1966-08-29	1971-08-25	Acraf	Indazol-3-yl-oxyalkanoic acids and process for the preparation thereof
US3470298A (en) *	1969-01-29	1969-09-30	Acraf	Topical anti-inflammatory composition containing (indazole-3-yl)-oxyalkanoic acids
IT1131779B (it)	1980-07-29	1986-06-25	Acraf	Sale dell'acido (1-benzil-1h-indazol-3-il)-ossiacetico con la lisina e procedimento per la sua preparazione
IT1189052B (it)	1981-11-27	1988-01-28	Acraf	Trattamento della cataratta
IT1194564B (it)	1983-04-18	1988-09-22	Acraf	Impiego del bendazac e dei suoi sali nel trattamento della retinite pigmentosa
IT1197805B (it)	1986-08-01	1988-12-06	Acraf	Metodo per il tratamento di lenti a contatto

1989
- 1989-02-07 IT IT8947620A patent/IT1230441B/it active
1990
- 1990-01-22 IL IL9313290A patent/IL93132A/en not_active IP Right Cessation
- 1990-01-23 ES ES90200167T patent/ES2020171T3/es not_active Expired - Lifetime
- 1990-01-23 DE DE69021902T patent/DE69021902T2/de not_active Expired - Lifetime
- 1990-01-23 EP EP90200167A patent/EP0382276B1/fr not_active Expired - Lifetime
- 1990-01-23 AT AT90200167T patent/ATE127115T1/de not_active IP Right Cessation
- 1990-01-23 DE DE199090200167T patent/DE382276T1/de active Pending
- 1990-01-23 DK DK90200167.6T patent/DK0382276T3/da active
- 1990-01-24 US US07/470,118 patent/US4999367A/en not_active Expired - Lifetime
- 1990-01-26 NZ NZ232258A patent/NZ232258A/en unknown
- 1990-01-29 ZA ZA90644A patent/ZA90644B/xx unknown
- 1990-01-30 IN IN81/CAL/90A patent/IN170957B/en unknown
- 1990-01-30 PE PE1990164654A patent/PE25091A1/es unknown
- 1990-02-02 AU AU49066/90A patent/AU624895B2/en not_active Expired
- 1990-02-05 PL PL90285287A patent/PL163730B1/pl unknown
- 1990-02-05 YU YU20690A patent/YU47943B/sh unknown
- 1990-02-05 PL PL90283638A patent/PL163720B1/pl unknown
- 1990-02-05 RO RO144074A patent/RO106252B1/ro unknown
- 1990-02-06 RU SU904743128A patent/RU2066318C1/ru active
- 1990-02-06 AR AR90316095A patent/AR247386A1/es active
- 1990-02-06 HU HU90689A patent/HU204793B/hu unknown
- 1990-02-06 EG EG6290A patent/EG19170A/xx active
- 1990-02-06 JP JP2027007A patent/JP2870925B2/ja not_active Expired - Lifetime
- 1990-02-06 UA UA4743128A patent/UA26852C2/uk unknown
- 1990-02-06 FI FI900577A patent/FI102678B/fi active IP Right Grant
- 1990-02-06 BG BG091122A patent/BG50273A3/xx unknown
- 1990-02-06 SK SK563-90A patent/SK56390A3/sk not_active IP Right Cessation
- 1990-02-06 CZ CS90563A patent/CZ280121B6/cs not_active IP Right Cessation
- 1990-02-06 PT PT93067A patent/PT93067B/pt active IP Right Grant
- 1990-02-06 PH PH40002A patent/PH26552A/en unknown
- 1990-02-07 CA CA002009503A patent/CA2009503C/fr not_active Expired - Lifetime
- 1990-02-07 CN CN90100599A patent/CN1046505C/zh not_active Expired - Fee Related
- 1990-02-07 DD DD90342349A patent/DD295363A5/de unknown
- 1990-02-07 KR KR1019900001453A patent/KR0145525B1/ko not_active Expired - Fee Related
- 1990-02-07 DD DD90337657A patent/DD291995A5/de unknown
- 1990-12-20 US US07/632,117 patent/US5112986A/en not_active Expired - Lifetime
1991
- 1991-06-05 RU SU914895540A patent/RU2044729C1/ru active
- 1991-06-05 RU SU914895526A patent/RU2055071C1/ru active
- 1991-11-15 GR GR91300073T patent/GR910300073T1/el unknown
1993
- 1993-06-22 LV LVP-93-647A patent/LV10612B/lv unknown
- 1993-07-26 GE GEAP19931214A patent/GEP19971030B/en unknown
- 1993-08-17 LT LTIP872A patent/LT3604B/lt not_active IP Right Cessation
- 1993-09-15 CN CN93117740A patent/CN1034016C/zh not_active Expired - Fee Related
1995
- 1995-11-22 GR GR950403284T patent/GR3018165T3/el unknown

Also Published As

Publication number	Publication date
LV10612B (en)	1995-08-20
ES2020171A4 (es)	1991-08-01
PL163730B1 (pl)	1994-04-29
FI900577A0 (fi)	1990-02-06
YU20690A (sh)	1992-07-20
IT8947620A0 (it)	1989-02-07
IL93132A (en)	1994-05-30
PT93067B (pt)	1995-12-29
SK278441B6 (en)	1997-05-07
RU2044729C1 (ru)	1995-09-27
CZ280121B6 (cs)	1995-11-15
YU47943B (sh)	1996-07-24
DD291995A5 (de)	1991-07-18
ATE127115T1 (de)	1995-09-15
AU624895B2 (en)	1992-06-25
SK56390A3 (en)	1997-05-07
CN1046505C (zh)	1999-11-17
CA2009503A1 (fr)	1990-08-07
BG50273A3 (en)	1992-06-15
LTIP872A (en)	1995-03-27
HU204793B (en)	1992-02-28
EP0382276B1 (fr)	1995-08-30
HU900689D0 (en)	1990-04-28
IT1230441B (it)	1991-10-23
AU4906690A (en)	1990-08-16
ES2020171T3 (es)	1995-12-01
DE69021902T2 (de)	1996-05-23
ZA90644B (en)	1991-01-30
LV10612A (lv)	1995-04-20
RO106252B1 (ro)	1993-03-31
PE25091A1 (es)	1991-08-17
DE382276T1 (de)	1991-11-28
US5112986A (en)	1992-05-12
CN1044810A (zh)	1990-08-22
RU2055071C1 (ru)	1996-02-27
EP0382276A3 (en)	1990-12-12
EP0382276A2 (fr)	1990-08-16
GEP19971030B (en)	1997-06-13
PT93067A (pt)	1990-08-31
CN1088201A (zh)	1994-06-22
JP2870925B2 (ja)	1999-03-17
KR0145525B1 (ko)	1998-08-17
IL93132A0 (en)	1990-11-05
FI102678B1 (fi)	1999-01-29
UA26852C2 (uk)	1999-12-29
DE69021902D1 (de)	1995-10-05
NZ232258A (en)	1991-06-25
KR900012913A (ko)	1990-09-03
LT3604B (en)	1995-12-27
PH26552A (en)	1992-08-19
CN1034016C (zh)	1997-02-12
CZ56390A3 (en)	1995-06-14
US4999367A (en)	1991-03-12
CA2009503C (fr)	2000-04-11
EG19170A (en)	1994-11-30
DK0382276T3 (da)	1996-01-15
JPH02240065A (ja)	1990-09-25
AR247386A1 (es)	1994-12-29
FI102678B (fi)	1999-01-29
RU2066318C1 (ru)	1996-09-10
GR3018165T3 (en)	1996-02-29
GR910300073T1 (en)	1991-11-15
HUT53088A (en)	1990-09-28
PL163720B1 (pl)	1994-04-29
IN170957B (fr)	1992-06-20

Legal Events

Date	Code	Title	Description
2004-04-28	IF04	In force in the year 2004	Expiry date: 20100208

Publication	Publication Date	Title
EP0013376B1 (fr)	1982-05-19	Dérivé d'isoxazole, procédé pour sa préparation et composition le contenant
DD295363A5 (de)	1991-10-31	Verfahren zur herstellung von 1-benzyl-indazol-3-yl-zwischenprodukten
DE69232270T2 (de)	2002-08-08	Benzimidazol-derivate, verfahren zu ihrer herstellung und ihre anwendung in den gebieten therapeutik und kosmetik
DE2501834C2 (de)	1987-01-08	Neue Appetitzügler
DE2511647A1 (de)	1975-09-25	Neue benzopyranderivate
DE2253914C3 (de)	1976-11-25	Chromon-3-acrylsaeuren, verfahren zu ihrer herstellung sowie diese verbindung enthaltende arzneimittel
DE2307828A1 (de)	1973-08-23	(4-benzothiazolyl)-phenylessigsaeuren
DE1493083C (fr)	1973-03-22
DE2526089C3 (de)	1979-05-17	Sauerstoff-heterocyclische Essigsäuren, Verfahren zur Herstellung derselben und diese Verbindungen enthaltende Arzneimittel
DE1618465B2 (de)	1978-09-28	Phenylessigsäureester, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2328060B2 (de)	1975-05-15	5-substituierte 3-Methylbenzo eckige Klammer auf b eckige Klammer zuthienyl (2)-essigsauren, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
DE3235850A1 (de)	1983-08-11	Neue indolessigsaeureesterderivate und verfahren zur herstellung derselben
DE1493083B1 (de)	1972-08-17	Linolsaeureamide und Verfahren zu ihrer Herstellung
EP0017705A1 (fr)	1980-10-29	Dérivés de phénylalanyl-tryptophane, médicaments les contenant, leur préparation et leur utilisation
DE2412388A1 (de)	1974-09-19	Dibenzothiophenderivate, verfahren zu deren herstellung und sie enthaltende arzneimittel
DE3242442A1 (de)	1983-05-26	Benzylidenderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE3019834C2 (de)	1983-08-04	Ester von 2-(4-Isobutylphenyl)-propanol-1, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2609574B2 (de)	1977-10-27	1-(4-fluor-3-trifluormethylthio- phenyl)-piperazin, dessen salze, verfahren zu dessen herstellung und arzneimittel
EP0009153B1 (fr)	1981-10-14	Acides delta-hydroxycarboxyliques halogénés, procédé pour leur préparation et médicaments les contenant
DE2146676A1 (de)	1972-03-23	Cyclopropano- eckige Klammer auf b eckige Klammer zu -tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung
DE2505813C3 (de)	1978-08-24	2-(4-Isobutylphenyl)-buttersäure, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
EP0007347A1 (fr)	1980-02-06	Dérivés de alkylène glycol abaissant le taux en lipide et procédés pour leur préparation.
DE2557517C3 (de)	1978-01-26	Phenylessigsäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AT284094B (de)	1970-08-25	Verfahren zur herstellung von neuen aryl-substituierten, teilweise gesaettigten bicycloaryloxyalkancarbonsaeuren und derivaten davon
DE2243305C3 (de)	1976-04-22	Neue Derivate von Phenylessigsäure, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen, die die Derivate als Wirkstoff enthalten